Cardio Renal
CardioRenal has developed the world’s first connected medical device allowing chronic patients to measure their blood potassium levels on their own. Initially, we will target patients with CKD for whom our device will considerably improve day-to-day treatment.
In 2023 we are starting the FDA approval process.
This is a key step in our company development and we are really excited about it. In the USA, remote patient monitoring is a practice that is exploding.
